A study of ciclesonide nasal spray in patients 18 years and older with seasonal allergic rhinitis (BY9010/M1-413)

Study identifier:BY9010/M1-413

ClinicalTrials.gov identifier:NCT00384475

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized, double-blind, placebo-controlled, parallel-group study using the Environmental Exposure Chamber (EEC) to assess the Onset of Action of Ciclesonide, applied as a Nasal Spray (200 mcg, once daily), in the treatment of Seasonal Allergic Rhinitis (SAR) in patients 18 years and older

Medical condition

Rhinitis, Allergic, Seasonal

Phase

Phase 3

Healthy volunteers

No

Study drug

Ciclesonide Nasal Spray

Sex

All

Actual Enrollment

500

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Oct 2006
Primary Completion Date: 01 Jan 2007
Study Completion Date: 01 Jan 2007

Study design

Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria